and RBV dose reduction or discontinuation. 2, 3 The introduction of direct-acting antivirals (DAAs) has changed the HCV therapeutic landscape completely, and currently, in more than 90% of patients, viral clearance is achieved with these highly effective agents. [4] [5] [6] [7] Despite this development, and in contrast to PEG-IFN, RBV
has not left the therapeutic arena and is still used as an additive under certain circumstances such as presence of cirrhosis, genotype 3 infection, presence of resistance-associated substitutes, previous antiviral treatment failure and/or in specific DAA regimens to increase treatment efficacy. 8 Unfortunately, RBV is also associated with serious side effects, of which the most concerning is haemolytic anaemia. 9 Moreover, a high RBV plasma level is known to be associated with anaemia. 10 Despite weight-based dosing of RBV, the measured plasma levels vary widely between individuals, 11 whereas variability within an individual is minimal. 12 Studies investigating the association between RBV steady-state plasma level and sustained virological response (SVR) in HCV monoand HIV/HCV co-infected patients show contradictory results, possibly due to their small sample sizes and retrospective nature. [13] [14] [15] [16] Moreover, studies on RBV steady-state plasma levels in DAA-treated patients are scarce. Therefore, in a large cohort of HCV-infected patients treated with DAAs in combination with RBV, we assessed if there is an association between RBV steady-state plasma levels and SVR.
2 | ME TH ODS
| Study design and participants
This prospective cohort study was conducted in four Dutch academic medical centres (Erasmus MC University Medical Center Rotterdam, University Medical Center Utrecht, Radboud university medical center and University Medical Center Groningen). Consecutive adult patients with chronic HCV infection (ie positive HCV RNA >6 months), in whom interferon-free treatment with DAAs (except telaprevir and boceprevir) and RBV was initiated from January 2015 until May 2016, were included.
Selection of DAA regimen and treatment duration was at the discretion of the physician and according to international and national guidelines. [17] [18] [19] RBV dosages were weight based (<75 kg: 1000 mg/ d and ≥75 kg 1200 mg/d) and administered twice daily with meals.
There were no strict rules of action following therapeutic drug monitoring at week 8, and RBV dose adjustment or discontinuation was at the decision of the physician. RBV plasma samples were obtained and analysed at treatment week 8 or later. Clinical and demographic data were prospectively collected. Furthermore, patient-reported adherence and adverse events (AEs) were collected from the electronic patient file.
The study protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the local ethics review board.
| Definitions
SVR was defined as the absence of HCV RNA ≥12 weeks after completing antiviral treatment. RBV steady-state plasma level was defined as RBV plasma level ≥treatment week 8. The lower cutoff for the RBV therapeutic range was determined by the optimal value for predicting SVR, and the upper cut-off was the optimal value for preventing significant anaemia (ie plasma haemoglobin
. 20 The presence of either cirrhosis, being treatment experienced (all genotypes), and/or having HCV genotype 3 infection were considered difficult-to-cure characteristics. 
| Measurement of RBV
Plasma RBV levels were measured by the pharmacy laboratories of the four participating centres. While four different analytical methods were used, all were validated using international standards. 23, 24 Moreover, all four centres participate in the Dutch external quality control proficiency testing programme for measurement of RBV, to ensure accuracy and comparability of these bioanalytical methods. 25, 26 All assays were able to measure RBV steady-state plasma levels within a 90%-110% limit of the spiked (weighed-in) "expert" concentrations. This is within the 20% threshold that is frequently used to describe accuracy in international external quality control or proficiency testing programmes. 27, 28 Used analytical methods were (1) high pressure liquid chromatography with ultraviolet detection (detection limit:
0.03-12.0 mg/L), 23 (2) liquid chromatography with tandem mass
liquid chromatography with tandem mass spectrometry detection 3 | RESULTS
| Study population characteristics
From January 2015 until May 2016, a total of 185 chronic HCV-infected patients started interferon-free treatment with a combination of DAAs and RBV. In two patients, SVR could not be determined due to lost to follow-up, and they were, therefore, excluded ( Figure S1 ). The characteristics of the 183 included patients are given in Table 1 . Median age in the study population was 57 (IQR, interquartile range 52-64) years, 79% was male, and the majority was of Caucasian (74%) or North African/Middle Eastern (12%) descent (Table 1) . The majority of patients had cirrhosis (60%), 6% of these patients had decompensated cirrhosis (all Child-Pugh B), and 24 (13%) were liver transplant recipients.
HCV genotypes 1a (38%), 1b (21%) and 3 (23%), were the most prevalent, and median baseline HCV RNA was 6.20 (5.82-6.54) log 10 IU/mL.
| Treatment characteristics
Distribution of applied DAA regimens is given in Table 2 . The majority of patients had either one (34%) or more (51%) difficultto-cure characteristics, with only 15% having none of these characteristics (Table 2 ). In 157 (86%) patients, adherence to RBV was reported. Median patient-reported adherence was 100% (range 75%-100%), with only one patient reporting adherence <80%.
Median RBV start dose was 13. All regimens include weight-based ribavirin.
end-of-treatment, as a result of RBV dose reductions and/or discontinuation. In 50 (27%) patients, RBV dose was adjusted, and in 16 (9%) patients, RBV was discontinued. Main reasons for dose reduction were anaemia (50%), other AEs (16%) or therapeutic drug monitoring (32%).
Regarding RBV start dose and dose reductions/discontinuations, there was no statistically significant difference between noncirrhotic patients and patients with compensated or decompensated cirrhosis (P = .50; P = .29; P = .53, respectively) (Table S1 ).
A total of 32 patients had anaemia (haemoglobin <10 g/dL) of which 9 had a haemoglobin <8 g/dL.
Median RBV steady-state plasma level in the full cohort was 2.66 (IQR 1.95-3.60) mg/L, and the inter-patient coefficient of variation (CV) for RBV steady-state plasma level was 50.5%. There was no significant correlation between average RBV dose and RBV steady-state plasma level (R = .03, P = .706). (Figure 3 ).
| Factors associated with SVR

| Renal function and RBV levels
Baseline eGFR was available in 177 patients (97%), of whom 103
had an eGFR ≥90, 64 eGFR 50-89, 9 eGFR <50, and only one patient had an eGFR <30 mL/min/1.73 m 2 . Remarkably, no significant difference was seen in RBV start dose between the groups. At treatment week 8, patients with an eGFR <50 had significantly more RBV dose reductions ( Presence of cirrhosis, being treatment experienced and hepatitis C genotype 3: score from "0" to "3," where every factor is scored as 1 point, and presence of none of the factors is scored as 0 points. , respectively (P < .0001) (Figure 4 ). This went parallel to lower haemoglobin levels at treatment week 8, with a significant higher proportion in the eGFR <50 group that developed significant anaemia (80% vs 31% vs 4%, P < .0001).
| DISCUSSION
In this prospective study, the influence of RBV steady-state plasma level on achieving SVR in HCV-infected patients treated with the combination of DAAs and RBV was determined. The main finding of this study is that a higher RBV steady-state plasma level is an independent predictor of achieving SVR. In addition, the optimal RBV steady-state plasma level therapeutic range that balances SVR with risk of anaemia was found to be 2.28-3.61 mg/L.
Despite the great successes of DAAs, some patients remain difficult-to-cure. 29 Adding RBV to DAAs in these patients can increase SVR rates. 8, 30 Studies in the interferon era established that higher RBV steady-state plasma levels were positively correlated with SVR. 12, 23, 31, 32 We similarly found that higher RBV steady-state plasma levels led to a 1.8-fold increase in SVR in DAA-treated patients. This demonstrates that higher RBV plasma levels are effective to improve response rates, particularly in difficult-to-cure patients with a lower a priori chance of achieving SVR. Possibly, therapeutic drug monitoring can help achieving these high RBV plasma levels.
A recent study including patients treated with sofosbuvir/RBV found no association between RBV steady-state plasma levels and SVR. 13 However, this study had a small sample size of 47 treatment naive, predominantly genotype 1-infected, noncirrhotic patients and retrospectively analysed RBV plasma samples. Moreover, SVR rates were low (55%), probably because sofosbuvir/RBV is a suboptimal treatment for genotype 1, 17, 18 and these results should, therefore, be carefully interpreted. Our study, however, represents a large realworld cohort of mainly difficult-to-cure patients on various DAA combinations with prospectively analysed plasma samples and SVR rates similar to clinical trials and real-world cohorts. 17, 18 In case the addition of RBV is considered beneficial and is administered, it is important to balance efficacy and side effects.
Although side effects of RBV in combination with DAAs are generally considered very mild, almost one in five of our patients developed significant anaemia. This study found an optimal RBV steady-state plasma level therapeutic range of 2.28-3.61 mg/L. Interestingly, this study as well as studies with triple-therapy including a first-generation DAA 32,33 found somewhat higher therapeutic ranges compared with studies done with PEG-IFN/RBV alone. 23, 34, 35 The most likely explanation for this is that PEG-IFN contributes to anaemia through bone marrow suppression and as such augments the toxicity of RBV at any given dose/concentration. Another explanation for this could be that with the excellent safety profile of DAAs, sicker patients than those in the PEG-IFN/RBV era can now be treated. 36 A significant proportion of our patients had (decompensated) 
